P-7600 PKC412, >99%

Synonyms : [CGP41251] [4'-N-Benzoyl Staurosporine] [Midostaurin]

Related Terms : [Rydapt]

Prices_reduced
  • Size
  • US $
  • €
  • £
  • ¥
  • 1 mg
  • 41
  • 40
  • 33
  • 5,400
  • Add to Cart
  • Out of stock
  • 5 mg
  • 99
  • 97
  • 81
  • 13,100
  • Add to Cart
  • Out of stock
  • 10 mg
  • 166
  • 162
  • 137
  • 22,000
  • Add to Cart
  • Out of stock
  • 25 mg
  • 331
  • 324
  • 273
  • 43,900
  • Add to Cart
  • Out of stock
  • 50 mg
  • 459
  • 449
  • 379
  • 60,900
  • Add to Cart
  • Out of stock
  • 100 mg
  • 775
  • 759
  • 640
  • 102,800
  • Add to Cart
  • Out of stock
  • 200 mg
  • 1,290
  • 1,264
  • 1,066
  • 171,100
  • Add to Cart
  • Out of stock
  • 500 mg
  • 1,870
  • 1,832
  • 1,546
  • 248,100
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
Compare Quality and Prices — LC Labs vs. Other Suppliers
  • M.W. 570.64
  • C35H30N4O4
  • [120685-11-2]
  • M.I. 14: 6185

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 5 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • The staurosporine analog, PKC412, inhibits a variety of serine/threonine and tyrosine kinases including PKC (IC50 = 50 nM), cyclic AMP-dependent protein kinase (IC50 = 2.4 µM), S6 kinase (IC50 = 5.0 µM), and EGFR (epidermal growth factor receptor) tyrosine-kinase activity (IC50 = 3.0 µM). Meyer, T., et al. "A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity." Int. J. Cancer 43: 851-856 (1989).
  • PKC412 inhibits autophosphorylation of platelet-derived growth factor (PDGF) receptor in BALB/c 3T3 cells at submicromolar concentrations. Andrejauskas-Buchdunger, E. and Regenass, U. "Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251." Cancer Research, 52: 5353-5358 (1992).
  • PKC412 strongly blocks the proliferation of ras-transformed pancreatic cancer cells (TUC-3) by causing apoptosis and induction of phenotypic reversion. Way, D., et al. "A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti-ras peptide." Cancer Chemother. Pharmacol. 49: 429-437 (2002).
  • PKC412 suppresses Akt activity by blocking serine phosphorylation in the kinase activation loop and induces apoptosis in myeloma cell lines. Bahlis, N.J., et al. "N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells." Leuk. Lymphoma 46: 899-908 (2005).
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • PKC412 selectively inhibits T lymphocyte production of TNF-α (tumor necrosis factor - alpha) with an IC50 of 0.5 µM. Si, M.S., et al. "Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production." Int. Immunopharmacol. 5: 1141-11419 (2005).
  • Not available in some countries; not available to some institutions; may not be sold for some uses.
249